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The psychiatric morbidity among cancer patients has been esti-
mated previously and it has been found that approximately
25–30% of all cancer patients develop clinically significant
anxiety or depression within 2 years of diagnosis (Maguire, 1992;
Greer, 1994). Several risk factors for development of psychiatric
disorder have been identified and examined. These factors relate to
patient characteristics, disease and treatment, interaction between
patients and illness, and environment (Harrison and Maguire,
1994; Harrison et al, 1994).
Head and neck cancer patients’ psychiatric morbidity has been
studied in cross-sectional studies (Morton et al, 1984; Espie et al,
1989; Rapoport et al, 1993; Bjordal and Kaasa, 1995; McDonough
et al, 1996) and prospectively (Davies et al, 1986; Baile et al,
1992; Hammerlid et al, 1997a, 1997b). The level of mental
distress among these patients corresponds with those found for
other cancer locations. The determining risk factors for develop-
ment of psychiatric morbidity among head and neck cancer
patients have been suggested to include tumour stage, perfor-
mance status, lack of social support and low social functioning,
co-morbidity, previous psychiatric disease, pain and malnutrition
(Shapiro and Kornfeld, 1987; Westin et al, 1988; Baile et al, 1992;
Bjordal and Kaasa, 1995; McDonough et al, 1996; McQuellon and
Hurt, 1997), but no single consistently strong risk factor has yet
been found.
For this study, a protocol was designed to enable a descriptive,
prospective Swedish/Norwegian multicentre quality of life (QL)
study of a large sample of head and neck cancer patients accrued
during a short period of time to be performed (Bjordal et al, 1993).
The study design was tested and proved feasible in a previous
study (Hammerlid et al, 1997a). The battery of questionnaires
found sensitive to change over time in this cancer population
included, apart from the Hospital Anxiety and Depression scale
(HAD) presented in this paper, the European Organization for
Research and Treatment of Cancer Core 30 questionnaire (EORTC
QLQ-C30) and the EORTC head and neck cancer module,
(QLQ-H&N35). The entire set of questionnaires was presented to
357 newly diagnosed head and neck cancer patients six times
during 1 year at different hospitals in Sweden and Norway. Results
using the EORTC questionnaire technique will be presented
elsewhere (Hammerlid et al, unpublished data; Bjordal et al,
unpublished data).
This paper is concerned with the mental distress aspects and
presents the results of the HAD scale designed to screen for
psychiatric morbidity. The aim was threefold: to determine the
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level of mental distress before, during and after treatment in head
and neck cancer patients and the prevalence of probable mood
disorder; to explore relationships between mental distress and
tumour location, stage, performance status, age, sex and marital
status; and to analyse the factor structure and stability of the HAD
scale since the empirical evidence of a two-dimensional structure
(anxiety and depression) is not unequivocal (Razavi et al, 1990;
Brandberg et al, 1992).
PATIENTS AND METHODS
Study design
Patients were recruited from the University Hospitals of Göteborg,
Malmö and Lund in Sweden, and the Norwegian Radium Hospital
and the National Hospital in Oslo, Norway, in 1993–1994. All
adult patients with an untreated primary head and neck cancer
(ICD-9 141–148, 160, 161 and 196) were invited consecutively to
participate in the study at all inclusion centres. Patients who were
thought to be unable to answer the QL questionnaires due to senile
dementia, mental disturbance or severe intercurrent disease were
excluded, as were patients with lymphoma, malignant melanoma
or skin cancer in the head and neck region. There was no limitation
regarding age or performance status.
Patients answered the questionnaires at the time of diagnosis
and then 1, 2, 3, 6 and 12 months after the treatment had started.
The first questionnaire was given to the patients at the weekly
tumour conference at each centre. The other questionnaires were
mailed to the patients at the appropriate time. If the patients did not
return the questionnaire within 10 days, they were reminded
once. A completed questionnaire at diagnosis was a prerequisite
for inclusion and was regarded as the patient’s informed consent to
inclusion. The study was approved by the local ethics committees.
At inclusion, the tumour location according to ICD-9, tumour,
node and metastasis (TNM) classification (UICC, 1987), SNO
med code for histopathology, planned treatment and curative
or palliative intent were noted. The clinical data included co-
morbidity, weight, height, weight loss (during the last 3 months),
time of onset of tumour-related symptoms and Karnofsky
Performance Status (KPS) (Karnofsky et al, 1948). After 13
months, current weight, KPS, treatment received and treatment
response were noted together with present tumour status.
QL questionnaires
HAD scale
The HAD scale, the focus of this paper, has been designed to
screen for psychiatric morbidity in patients with somatic illness. It
comprises two scales, one for depression (seven questions) and
one for anxiety (seven questions). The questionnaire has been
constructed so that somatic questions are avoided. Cut-offs
have been established for when to regard a patient as a probable
(> 10 points, on one scale) or possible (> 7, on one scale) case
of psychiatric illness (Zigmond and Snaith, 1983).
The HAD scale has been extensively documented in patients
with cancer in many countries and its validity has been examined
in a variety of diagnostic groups (Aylard et al, 1987; Barczak et al,
1988; Razavi et al, 1990; Hopwood et al, 1991; Moorey et al,
1991; Caroll et al, 1993; Sullivan et al, 1993; Ibbotson et al, 1994).
It has also been used in Scandinavia to screen for psychiatric
illness among head and neck cancer patients (Hammerlid et al,
1997a, 1997b) as well as among patients with other types of
cancer (Bergman et al, 1991; Brandberg et al, 1992, 1995; Nordin
et al, 1996).
Study-specific questionnaire
This questionnaire contained eight self-reported questions relating
to family, education, work and smoking habits.
Patients
A total of 357 patients were included in the study; 111 patients in
Oslo, 106 in Malmö/Lund and 140 in Göteborg. The recruitment
period varied from 12 to 18 months due to local circumstances.
The study population is described in Table 1. The mean age was 63
years (range 18–88) and the majority were males (72%). The most
common subgroup of head and neck cancer (n = 122) was oral
cavity tumours (ICD 143 gingival; 144 floor of the mouth; 145
other oral and oral tongue). Eighty-nine patients had pharyngeal
cancer (ICD 146 tonsils; 147 nasopharynx; 148 hypopharynx and
tongue base carcinoma), 86 laryngeal carcinoma and 60 patients
had ‘other’ tumour locations (ICD 142 salivary glands; 160 nose
and sinuses; 196 unknown primary). At diagnosis, 46 patients
(13%) were under treatment for hypertension or heart failure, 30
patients (8%) for pulmonary problems and 70 patients (20%) for
another disease. Less than 10% had been treated for a previous
malignancy (n = 25).
Table 1 Background treatment and follow-up data for the whole study group and selected subgroups
Total group Male Female Oral cavity Pharynx Larynx Other
Number 357 256 (72%) 101 (28%) 122 89 86 60
Females 101 (28%) 40 (33%) 27 (30%) 14 (16%) 20 (33%)
Mean age 63 63 61 62 59 66 65
Stagea I+II 141 (41%) 103 (41%) 38 (40%) 56 (46%) 14 (16%) 55 (64%) 16 (33%)
III+IV 204 (59%) 146 (59%) 58 (60%) 65 (54%) 75 (84%) 31 (36%) 33 (67%)
Rt 314 (88%) 232 (89%) 86 (85%) 96 (79%) 85 (96%) 82 (95%) 51 (85%)
BT 56 (16%) 39 (16%) 17 (17%) 29 (24%) 24 (27%) 0 7 (12%)
Chemo 68 (19%) 46 (18%) 22 (22%) 13 (11%) 33 (37%) 8 (6%) 13 (22%)
Surgery 133 (37%) 86 (34%) 47 (47%) 79 (65%) 10 (11%) 7 (8%) 37 (62%)
Relapse 56 (16%) 38 (15%) 18 (18%) 24 (20%) 10 (11%) 13 (15%) 9 (15%)
Survival 280 (78%) 198 (76%) 82 (81%) 90 (74%) 66 (74%) 74 (86%) 48 (80%)
a Stage is missing for 12 patients: one gingival carcinoma, seven sinus and nose carcinoma, and four tumour colli. Rt: External radiation therapy; BT:
Brachytherapy; Chemo: chemotherapy; Surgery: surgery towards the primary tumour; Relapse: relapse within the study-year; Survival: Survival rate
after 1 year.768 E Hammerlid et al
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Sociodemographic data
At diagnosis, 62% of the patients were retired and 30% were
working. The remainder were studying or unemployed. Thirty
patients (9%) had children living in their household. Ninety-nine
patients (28%) were living alone. More than half of the patients
had only compulsory school education (58%) and the rest had
college or university education.
Treatment and follow-up
Treatment and follow-up after 1 year are shown in Table 1. The
majority of patients had combined treatment; most of them had
external radiation therapy. The mean radiation dose for the primary
tumour was 60 Gy and the mean regional node dose was 46 Gy.
Fifty-six patients received interstitial radiation therapy, all but two
were treated in Göteborg.
A total of 133 patients (37%) underwent primary tumour
surgery and 57 patients (16%) had a neck dissection. Sixty-eight
patients (19%) were treated with chemotherapy, mainly in
Göteborg. All but three patients were given two or three cycles of
cisplatin (CDDP) in combination with 5-fluorouracil.
Of the 56 relapses, 33 were local, 22 regional and 14 patients
had distant metastasis (13 patients had a combined local and
regional relapse). No additional treatment was given in 15
cases; the others received salvage surgery (n = 25), palliative
chemotherapy (n = 8) or radiation therapy (n = 4) (information
missing in four cases).
The mean KPS was 89 at the 1-year follow-up, compared to 92
at diagnosis (value 0–100). At the 1-year follow-up, 234 patients
(65%) were alive and tumour-free without being treated for any
relapse, 14 patients (4%) had been treated for one relapse but were
tumour-free at the 1 year control, while 32 patients (9%) had an
active tumour disease. Seventy-seven patients were dead, 50
(14%) due to the head and neck cancer, three patients (1%) due to
another cancer, 14 patients (4%) due to another disease and ten
patients (3%) had died of unknown causes. Thus, the overall
survival rate after 1 year was 78%.
Statistical analysis
For comparison between two groups, Fisher’s non-parametric
permutation test was applied and for analysing proportions
between groups Fisher’s exact test was used (Bradley, 1968a,
1968b). To test relationships between variables, Pitman’s non-
parametric permutation test (Bradley, 1968) was the preferred
method. In order to adjust for confounding variables, a non-para-
metric partial correlation analysis based on Mantel’s technique of
pooling (Mantel, 1963) applied to Pitman’s non-parametric permu-
tation test was used. Pearson’s correlation coefficient was used
for descriptive purposes. The significance level was set at 5%
throughout. A logistic regression analysis was performed to
identify predictors of mental disturbance.
To test the two-dimensional structure of the HAD scale, prin-
cipal components and common factor analysis (orthogonal rota-
tion) were performed at diagnosis (Nunnally and Bernstein, 1994).
Further, multitrait analysis was applied to test internal consistency
(how much each question contributes to the anxiety or depression
scale) and discriminant validity (how specific each anxiety
question is in relation to the depression dimension and vice versa)
(Nunnally and Bernstein, 1994). Cronbach’s coefficient was
reported as an estimate of the internal consistency reliability
(Cronbach, 1951).
To avoid multiple significance testing, we selected three of
the six measurement points: at diagnosis (before treatment), at
3 months (just after finishing treatment), when symptoms and
problems are at their peak (Hammerlid et al, 1997a), and at the
1-year follow-up. The significance testing included only those
patients who completed 3 months (n = 261) and 12 months
(n = 215) follow-up respectively.
RESULTS
Longitudinal data will be presented for the whole study group as
well as for different subgroups of patients with respect to sex,
age, tumour stage and tumour location.
Compliance
Patients consecutively referred to the weekly tumour conferences
at the different centres were asked to participate. A total of 357
patients agreed to participate and answered the first questionnaire
(one questionnaire missing). Three hundred and six patients of 345
alive answered the second questionnaire one month after the start
of treatment (89%), 290 of 330 (88%), surviving patients answered
the third questionnaire 2 months after the start of treatment, 261 of
315 (83%) surviving patients answered the fourth questionnaire
3 months after the start of treatment, 239 of 309 (77%) the fifth
questionnaire 6 months after the start of treatment and 215 of 280
(77%) patients alive answered the sixth questionnaire 1 year after
the start of treatment.
Questionnaire
Performance of the questionnaire
Few patients were omitted due to missing data (n = 6, 1.7%, at
diagnosis). The mean score was 4.75 for the anxiety scale and 3.8
for the depression scale. There were more floor than ceiling
effects, i.e. 9% of the patients scored zero on the anxiety scale,
compared to 15% on the depression scale. Only 0.3% of the
patients achieved the maximum score on either of the scales.
Cronbach’s a (internal consistency) was 0.89 and 0.82 for the
anxiety and depression scales respectively, i.e. well above the limit
of 0.70. The Pearson correlation coefficient for each question
versus the two scales showed that all questions in both scales
correlated higher with their own scale, corrected for overlap, than
with the other scale. The lowest within-scale correlation was found
for ‘I lost interest in my appearance’ (r = 0.37) (depression scale,
corrected for overlap). The anxiety dimension showed better
discriminant validity than the depression dimension, i.e. six of the
seven anxiety questions versus three of seven reflecting depression
correlated significantly higher with their own scale. The item
‘I can sit at ease and feel relaxed’ was unspecific, i.e. showed
substantial correlation with both dimensions. The psychometric
performance of the HAD scale seemed consistent over time since
the same psychometric results were found at 3 and 12 months.
Clinical results
Total study sample The longitudinal results from the HAD
scale for the whole study population are shown in Table 2. The
number of patients scoring as a probable or possible case of
anxiety disorder was highest at diagnosis (32%), after which theMental distress and morbidity in head and neck cancer patients 769
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number slowly decreased. At the 1-year follow-up every fifth
patient (20%) still scored above 7 on the anxiety scale. The highest
number of patients scoring above 7 on the depression scale
occurred 2 months after diagnosis (29%), i.e. during treatment,
while the lowest number was seen at diagnosis and at the 1-year
follow-up (17%). The number of patients scoring high on either of
the scales was highest at diagnosis (36%) but did not change very
much until the 1-year follow-up (26%). To find out if the changes
during the year were significant, we selected three target measure-
ment points out of six: at diagnosis, after finishing the treatment
(3 months) and the follow-up at 12 months. The changes between
diagnosis and 3 months (n = 261) were significant for both
possible and probable anxiety and depression (P < 0.01), while
between diagnosis and 12 months (n = 215) only the change for
probability of an anxiety disorder was significant (P < 0.01)
(data not shown).
At 3 and 12 months, we examined the proportion of patients that
scored the same (0–7, 8–10, or 11+) or had improved/deteriorated
compared to diagnosis (Table 3). The majority of the patients
(58–75%) scored as non-cases (score 0–7) on the anxiety or
depression scale at both 0–3 and 0–12 months. There were new
possible and probable cases of psychiatric illness at both 3 and
12 months, the largest number being found on the depression scale
at 3 months compared to diagnosis. The best improvement was
found on the anxiety scale between diagnosis and 3 months.
Subgroups of patients
Before any significance testing was performed between sex, stage,
age group, KPS and HAD scale score, we examined potential rela-
tionships between background variables. We found no significant
correlation between disease stage and age, between sex and age, or
between stage and sex, but a strong correlation indicating that
the lower the KPS, the more advanced was the tumour stage and
the lower the KPS, the higher the patient’s age (Pitman non-
parametric correlation coefficients, P < 0.001).
Subgroups of patients at diagnosis
The HAD results for different subgroups at diagnosis are
presented in Table 4. When comparing females with males, we
Table 2 Results from the HAD scale for all patients answering at each measurement point
Diagnosis 1 month 2 months 3 months 6 months 12 months
Number of patients 356 306 290 261 239 215
Poss. Anxiety 41 (12%) 29 (9%) 33 (11%) 35 (13%) 29 (12%) 20 (9%)
Prob. Anxiety 71 (20%) 44 (14%) 33 (11%) 31 (12%) 19 (8%) 23 (11%)
Poss. Depr 39 (11%) 45 (15%) 51 (18%) 30 (11%) 27 (11%) 19 (9%)
Prob. Depr 23 (6%) 34 (11%) 32 (11%) 34 (13%) 22 (9%) 18 (8%)
No pts > 7 on a scale 127 (36%) 104 (34%) 102 (35%) 89 (34%) 71 (30%) 55 (26%)
Questionnaire: Measurement point. Number of patients: number of patients answering the questionnaire. Poss. Anxiety: possible anxiety disorder, number of
patients scoring 8–10 on the anxiety scale. Poss. Depr: possible depression disorder, number of patients scoring 8–10 on the depression scale. Prob. Anxiety:
probable anxiety disorder, number of patients scoring 11 or more on the anxiety scale. Prob. Depr: probable depression disorder, number of patients scoring
11 or more on the depression scale. No pts > 7 on a scale: number of patients scoring > 7 on one scale; the patient is only counted once even if the scores
exceed 7 on both scales. %: Percentage of the patients scoring > 7, on one scale.
Table 3 Number of patients scoring better, worse or unchanged on the HAD scale between diagnosis and 3 months (n = 260) and
between diagnosis and 12 months (n = 214)
0–3 Months 0–12 Months
Anxiety Depression Anxiety Depression
New poss. cases 17 25 6 14
New prob. cases 13 26 4 14
New poss. + prob. cases 30 (12%) 51 (20%) 10 (5%) 28 (13%)
0–7 152 176 140 157
8–10 5 4 5 4
11+ 18 8 19 4
Unchanged score 175 (67%) 188 (72%) 164 (77%) 165 (77%)
Decrease of poss. cases 23 15 18 14
Decrease of prob. cases 32 6 22 7
Decrease of poss. + prob. cases 55 (21%) 21 (8%) 40 (19%) 21 (10%)
Poss. case: possible case of anxiety or depression disorder, score 8–10; prob. case: probable case of anxiety or depression disorder, score
11+. New poss. cases: number of patients that deteriorated from scoring normally at diagnosis (0–7) to scoring as possible cases of anxiety
or depression (8–10) at 3 months. New prob. cases: number of patients that deteriorated from scoring normally (0–7) or as a possible case
of anxiety or depression (8–10) at diagnosis to scoring as a probable cases of anxiety or depression (11+) at 3 months. Unchanged score:
number of patients that scored the same at both diagnosis and 3 months or diagnosis and 12 months. Decrease of poss. cases: number of
patients that improved from scoring as a possible case of anxiety or depression to normal score. Decrease of prob. cases: number of
patients that improved from scoring as a probable case of anxiety or depression to a possible case or normal score.770 E Hammerlid et al
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found a significantly higher prevalence of anxiety disorder for
females (P < 0.01). Further, they scored above 7 points on either of
the scales significantly more often (P < 0.01).
When patients before retirement were compared with patients
after retirement, the younger patients reported significantly more
anxiety (P < 0.01) and significantly more often scored above seven
on either of the scales (P < 0.05). This result was still valid after
adjusting for KPS.
Patients with advanced disease (stage III+IV) more often scored
as a possible or probable case of depression than patients with
small tumours (stage I+II) but the difference was not significant
(20% vs 14%). There was a significant correlation between KPS
and depression (P < 0.01) but not anxiety.
We did not find any significant difference when the tumour
locations were compared; the oral cavity tumour patients scored
above seven on either of the scales in 45% of the cases, compared
to 31% of the pharyngeal and laryngeal cancer patients and 28% of
those with ‘other tumours’.
We also tested if people living alone (n = 99) were at greater risk
of developing mental distress levels approaching psychiatric
morbidity than patients living with someone (n = 253), since
inadequate social support might be considered detrimental. People
living alone scored higher for ‘probable cases of depression’ (9%
versus 5%) and for ‘possible cases of anxiety’ (13% versus 6%)
but the differences were not significant. There was no significant
difference, at diagnosis, in the occurrence of anxiety or depression
Table 4 Results from the HAD scale at diagnosis for the whole study group and different subgroups for patients answering the questionnaire
Total Sex Age Stage
group
Male Female –64 65+ I+II III+IV
Number of pts 356 255 101 169 187 140 204
Poss. Anxiety 41 (12%) 26 (10%) 15 (15%) 20 (12%) 21 (11%) 12 (9%) 28 (14%)
Prob. Anxiety 71 (20%) 40 (16%) 31 (31%) 50 (30%) 21 (11%) 30 (21%) 38 (19%)
Prob. + Poss. Anxiety 112 (312%) 66 (26%) 46 (46%) 70 (42%) 42 (22%) 42 (30%) 66 (33%)
Poss. Depression 39 (11%) 24 (9%) 15 (15%) 21 (12%) 17 (9%) 15 (11%) 22 (11%)
Prob. Depression 23 (6%) 16 (6%) 7 (7%) 9 (5%) 14 (7%) 5 (4%) 18 (9%)
Prob. + Poss Depression 62 (17%) 40 (15%) 22 (22%) 30 (17%) 31 (16%) 20 (15%) 40 (20%)
No pts > 7 on a scale 127 (36%) 78 (30%) 49 (49%) 72 (43%) 55 (29%) 46 (33%) 77 (38%)
Karnofsky Tumour location
100–90 80 70– Oral Pharynx Larynx Other
Number pts 274 38 32 122 89 86 60
Poss. Anxiety 30 (11%) 6 (16%) 5 (16%) 25 (20%) 5 (6%) 8 (9%) 3 (5%)
Prob. Anxiety 52 (19%) 5 (13%) 11 (34%) 25 (20%) 17 (19%) 16 (19%) 13 (22%)
Prob. + Poss. Anxiety 82 (30%) 11 (29%) 16 (50%) 50 (40%) 22 (25%) 24 (28%) 16 (27%)
Poss. Depression 28 (10%) 5 (13%) 4 (13%) 12 (10%) 11 (12%) 13 (15%) 3 (5%)
Prob. Depression 14 (5%) 3 (8%) 6 (19%) 8 (7%) 8 (9%) 4 (5%) 3 (5%)
Prob. + Poss. Depression 42 (15%) 8 (21%) 10 (32%) 20 (17%) 19 (21%) 17 (20%) 6 (10%)
No pts > 7 on a scale 92 (34%) 15 (39%) 16 (50%) 55 (45%) 28 (31%) 27 (31%) 17 (28%)
Poss. Anxiety: possible anxiety disorder, number of patients scoring 8–10 on the anxiety scale. Prob. Anxiety:probable anxiety disorder, number of patients
scoring 11+ on the anxiety scale. Prob. + Poss. Anxiety: number of patients scoring as either a probable or possible case of anxiety. Poss. Depression: possible
depression disorder, number of patients scoring 8–10 on the depression scale. Prob. Depression: probable depression disorder, number of patients scoring
11+ on the depression scale. Prob. + Poss. Depression: number of patients scoring as either a probable or possible case of depression. No pts > 7 on a scale:
number of patients (%: percentage) scoring > 7 on one scale; the patient is only counted once even if the scores exceed 7 on both scales.
Table 5 The HAD scale and subgroupings by sex, age, stage and performance status at three measurement points
Diagnosis (n = 359) 3 months (n = 260) 12 months (n = 214)
Sex Anxietyb Anxiety Anxietya
Depression Depression Depression
> 7 on a scaleb > 7 on a scale > 7 on a scale
Age Anxietyb Anxiety Anxietyb
–64 vs. >65 Depression Depression Depression
> 7 on a scalea > 7 on a scale > 7 on a scale
Stage Anxiety Anxietya Anxiety
I+II vs. III+IV Depression Depression Depression
> 7 on a scale > 7 on a scale > 7 on a scale
Karnofsky Anxiety Anxiety Anxiety
Depressionb Depressiona Depressiona
> 7 on a scale > 7 on a scalea > 7 on a scale
Diagnosis, 3 months and 12 months: measurement points. The Table shows the significant differences in probability of anxiety and
depression between the sexes, age groups and stages, and the significant correlation between Karnofsky’s performance status and
the HAD. >7 on a scale means the number of patient scoring above 7 points on either anxiety or depression. aP < 0.05), bP < 0.01.Mental distress and morbidity in head and neck cancer patients 771
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disorder between the group of patients interrupting the study and
the group completing the study.
Longitudinal results for subgroups of patients
Since there were differences at diagnosis in the HAD score
depending on sex, age group, stage and KPS, we decided to
examine if there were any significant differences between these
subgroups at other time points. The HAD scores at three measure-
ment points were selected: at diagnosis, at 3 months and at 12
months. The numbers of patients scoring as probable or possible
cases of anxiety or depression are displayed in Figures 1–4 and the
significant differences between subgroups are shown in Table 5.
Female patients more often scored as probable or possible cases
of anxiety during the study-year (Figure 1A), the difference at
diagnosis and 12 months being significant (Table 5). There was no
significant difference in prevalence of depression between the
sexes (Figure 1B and Table 5).
Patients before retirement were more anxious than patients after
retirement at all measurement points (Figure 2A) and the differences
were significant at diagnosis and at 12 months (Table 5), while there
was no consistent difference between the two age groups when
comparing the number of patients scoring as probable or possible
cases of depression. Patients with large tumours more often scored
as probable or possible cases of anxiety and depression compared
with patients with small tumours (Figure 3A,B) but there was only
one significant difference (anxiety 3 months). Patients with low
KPS were more often depressed (Figure 4B) and the difference at
diagnosis and at 12 months was significant (Table 5).
In order to identify risk factors for developing mental distress or
psychiatric morbidity, a logistic regression analysis was performed
where age, sex, tumour site, tumour stage, KPS, living alone or not
and HAD score at baseline (possible or probable cases of anxiety
or depression) were considered potential predictors. The only
predictor found for psychiatric disturbence at twelve months was
probable and/or possible anxiety or depression at diagnosis.
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Figure 1 The percentage of females (F) versus males (M) who scored as a possible or probable case of anxiety (A) or depression (B) at the different
measurement points during the study year.
Figure 2 The percentage of patients, before and after retirement, who scored as a possible or probable case of anxiety (A) or depression (B) at the different
measurement points during the study year. < 65 years (before retirement) versus patients 65 years or older (after retirement)
50
0
40
30
20
10
%
Probable
Possible
Diagnosis Months 1 2361 2
A
<65³65 <65³65 <65³65 <65³65 <65³65 <65³65
50
0
40
30
20
10
Diagnosis Months 123 6 1 2
Probable
Possible
B
<65³65 <65³65 <65³65 <65³65 <65³65 <65³65
%772 E Hammerlid et al
British Journal of Cancer (1999) 80(5/6), 766–774 © Cancer Research Campaign 1999
DISCUSSION
This head and neck study sample was considered representative of
such patients in Sweden and Norway since a high percentage of
the patients that fulfilled the inclusion criteria were included
(Hammerlid et al, unpublished data) and the compliance rate was
high (77%). Compliance was worse for patients with an active
disease (56%) than for patients without tumour (80%) at the 1-year
follow-up. The results therefore probably underestimate the true
prevalence of psychiatric morbidity 1 year after diagnosis of head
and neck cancer since the results from this study have shown that
emotional distress and psychiatric morbidity are more common
among patients with low KPS and more advanced disease. We
excluded patients not able to answer the QL questionnaires and
patients with mental disturbance. However, not one patient was
excluded due to mental disturbance when we examined the reasons
for exclusion in one of the centres. We therefore consider this
exclusion criterion to be a minor problem.
The anxiety and depression scales displayed different ‘patterns’
over time. We found the highest number of patients with probable
or possible anxiety disorder at diagnosis, while the highest number
of patients with depression was found during treatment. There
were new cases of possible or probable mood disorder at each
measurement point (Table 3). We therefore conclude that it is
useful to include the HAD scale not only at diagnosis but repeat-
edly during the first year of treatment. It will thereby be possible to
identify patients in need of psychiatric consultation and treatment
continuously.
Females scored markedly worse than males on the anxiety scale
at diagnosis and at the one-year follow-up but not significantly so
at the other measurement points (Figure 1A). The same results
were found in two studies of psychological distress in mixed
cancer populations. In one study sample the patients received radi-
ation therapy (Maher et al, 1996) and in the other patients were
compared at different stages of their disease (Caroll et al, 1993). A
higher level of emotional distress for females was also found in a
study among gastrointestinal cancer patients (Nordin et al, 1996).
The results presented here are in line with the significantly lower
emotional functioning scores for females at diagnosis found in the
same study sample, using the EORTC QLQ-C30 (Hammerlid et al,
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unpublished data). It therefore seems likely that females are more
worried than males initially in the course of their cancer disease,
but not to the same extent over time. This finding is in contrast, at
least partly, to a general tendency in the literature that women
report more symptoms/problems than men (Ware et al, 1993).
Advanced stage and low performance status seemed to be the
major determinants of a high score on the HAD scales. Partial
correlation analyses of stage, KPS and HAD pointed to the
Karnofsky’s performance status as the stronger predictor. Patients
with an advanced disease more often receive combined treatment
than patients with small tumours. The treatment period is therefore
longer and the side-effects greater, which may influence the level
of psychiatric distress. We found that patients with a more
advanced disease (stage III+IV) reported more depression
(Figure 3B), but the strongest correlation between psychiatric
distress and the other tested variables was found for KPS
(Figure 4), which corresponds to findings by others, i.e. the lower
the performance status, the higher the level of psychological
distress (Razavi et al, 1990; Kaasa et al, 1993). Unfortunately,
physicians do not pay enough attention to the probability of
psychiatric disorders among advanced head and neck cancer
patients. This may be due to lack of training and insufficient
knowledge of the psychological aspects of the disease (Maguire,
1985).
Patients before retirement scored worse than patients after
retirement at diagnosis, and a correlation between age and the
level of mental distress was found at diagnosis and at the 1 year
follow-up (Figure 2). This result corresponded with an earlier
finding of poorer emotional functioning in younger patients
according to the EORTC QLQ-C30 (Hammerlid et al, unpublished
data) at diagnosis. Further, a recent study of patients with
advanced malignancies supports our results (Coates et al, 1997).
The psychometric analyses, at three time points, supported the
two-dimensional structure and stability of the HAD scale, in
agreement with previous results (Moorey, Greer et al. 1991).
The potential risk factors identified for development of psychi-
atric morbidity among head and neck cancer patients in this study
should increase health care providers’ awareness of which patients
are more likely to develop high levels of mental distress. This is of
value since early detection and treatment of psychiatric illness has
been found to improve outcome (Maguire et al, 1980), as has
targeted intervention for patients at high risk (Moorey et al, 1994).
CONCLUSIONS
We conclude that the HAD scale is a useful instrument for easy
and cheap screening for psychiatric morbidity in head and neck
cancer patients. In order to find all patients at risk of developing
psychiatric disorder, it has to be used repeatedly since there were
new cases of psychiatric morbidity at all measurement points. The
number of patients with increased levels of mental distress was
high throughout the study, anxiety being most common at diag-
nosis, while depression was most common during treatment. A
low performance status and an advanced disease are stronger risk
factors for mental distress than sex and age. The prevalence of
psychiatric morbidity found in this study emphasizes the impor-
tance of improved diagnosis and treatment.
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